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ABSTRACT 
 
The objective of this thesis was to determine the association among a cardiac 
workload marker (the rate pressure product [RPP]), working memory, and cortical 
amyloid-β (Aβ) burden in 63 cognitively normal midlife adults (average age = 62.8 
years-old) at risk for Alzheimer’s disease (AD). 
All subjects were recruited on the basis of reporting a first-degree family history 
of AD as well as significant subjective memory complains. Each subjects underwent 
18F-florbetapir PET imaging to measure neocortical Aβ aggregation. The PET 
standardized uptake values (SUV) of neocortical Aβ were summed and normalized to 
the whole cerebellum SUV, resulting in a region-to-cerebellum ratio (SUVr). Blood 
pressure and heart rate data were collected during an initial baseline visit with subjects 
at rest.  All assessments occurred between 0800 and 0900. After the collection of these 
measures, all subjects completed the Groton Maze Learning Test (GMLT; 
www.cogstate.com). The GMLT is an iPad-administered hidden maze learning test 
that differentially measures both spatial working memory and reasoning/problem 
solving cognitive functions. 
The results show a moderate positive correlation between cardiac workload (at 
rest) and cognitive impairment as measured by the GMLT; however, this result only 
holds for the 15 subjects with evidence of substantial neocortical amyloid aggregation 
(SUVr PET scan) (R2 = 0.30; p = .034). By comparison, no such relationship was 
observed for the 48 subjects without any evidence of cortical Aβ plaque burden (R2 = 
.02). With all 63 subjects considered together, there is a small-to-moderate 
  
relationship between neocortical Aβ burden and RPP (r = 0.261, ρ = .039), with 
increasing cardiac workload at rest associated with greater neocortical amyloidosis. 
This relationship remained significant after statistical control for body mass index (r = 
0.262, ρ = .040) and age (r = .258, ρ=.043). 
These results show a small-to-moderate relationship between increasing 
myocardial oxygen use (at rest) and neocortical amyloidosis in individuals at the 
preclinical stage of AD. 
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CHAPTER 1 
 
INTRODUCTION 
 
Alzheimer’s disease (AD) was first diagnosed more than 110 years ago and a 
disease modifying treatment has yet to be discovered (van Norden et al., 2012). The 
reason for the lack of treatment may be because the clinical symptoms, such as 
dementia, are the result of massive brain damage that is most likely irreversible by the 
time a patient presents with moderate-to-severe disease (Gottfries,1984; Filley 1995). 
Given the difficulties of treating AD once it has been clinically diagnosed, we have 
focused our research on the preclinical stage of AD.  The preclinical stage of AD is 
believed to have its onset up to several decades prior to clinical diagnosis (Sperling et 
al., 2011), and it is now the stage of the disease targeted by several large secondary 
prevention trials (Sperling et al., 2014; Tarriot, 2016).  
However, identification of the preclinical stage is problematic: behavioral 
presentations of cognitive impairments and functional status are heterogeneous across 
individuals. In addition, many individuals at the pre-clinical stage of AD are healthy 
older adults and routine neurologic and/or neuropsychological exams are typically 
unremarkable. Hence, any efforts to improve our ability to identify ‘at-risk’ 
individuals in the preclinical stage of AD, such as detecting subtle alterations in 
concomitant cardiovascular function, would be valuable. 
Recent reports call into question the strength of the association between AD, 
cardiovascular and cerebrovascular diseases, despite the common knowledge that   
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these diseases affect the same at-risk population and share many of the same risk 
factors (Skoog et al., 1999; Martins et al., 2006; Profenno et al., 2009). Unfortunately, 
very little is known about the mechanism linking vascular changes with AD and even 
less is known about how early in the course of AD vascular changes can be detected. 
Hence, to explore whether there is any evidence of cardiovascular change that 
may be related to preclinical AD we chose to obtain measurements for a well-known 
cardiac workload marker [rate pressure product (RPP)] at rest, and during a 
challenging cognitive task, in subjects with different levels of cortical Aβ. RPP has 
been previously shown to be associated with relative impairments in older adults, 
compared to a younger comparison group, in response to the presentation of a 
challenging cognitive task (Matthewson et al., 2011), providing evidence that healthy 
older adults demonstrate increased cardiac oxygen demands during their response to a 
mildly stressful cognitive task.  In our study, we predicted that RPP would be 
increased for preclinical AD in comparison to healthy older adults, and that increased 
RPP would correlate with (impaired) performance on a spatial working memory test. 
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
AD and CVD share important cardiometabolic and lifestyle risk factors that 
occur in middle-aged to elderly populations.  Both AD and CVD are associated with 
increasing age, and both are among the leading causes of death in elderly populations.  
The primary causes of CVD are coronary heart disease (CHD), hypertension, stroke, 
and heart failure. These diseases are frequently interconnected and share an underlying 
pathology of atherosclerosis. All known risk factors for atherosclerosis have been the 
focus of studies to identify modifiable risk factors for AD.  Researchers from the 
Framingham Heart Study (Dawber et al., 1951; Harrison et al., 2014) developed a 
composite measure of general cardiovascular risk, the Framingham Cardiovascular 
Risk Profile (FCRP), derived by evaluating a patient’s age, gender, diabetes status, 
smoking behavior, treated and untreated systolic blood pressure (SBP), total 
cholesterol, and high density lipoprotein (HDL) cholesterol (Kanne et al., 1956).  
Other scores developed from the Framingham Heart Study, the Framingham 
Stroke Risk Profile and the Framingham Coronary Heart Disease Risk Score, have 
been similarly associated with cognitive change over time, incident cognitive 
impairment, and dementia (Harrison et al., 2014;Viticchi et al., 2015; Laughlin et al., 
2011; Dreagan et al., 2013; Kaffashian et al., 2011; Kaffashian et al., 2013; Unverzagt 
et al., 2006).  These risk scores are similar to one developed specifically to assess 
dementia risk, i.e. the Cardiovascular Risk Factors Aging and Dementia (CAIDE) risk 
 5 
 
score (Kivipelto et al., 2006; Virta et al., 2013; Exalto et al., 2013).  Obesity, 
dyslipidemia, high blood pressure and metabolic syndromes are precursors to, or 
develop along with, atherosclerosis, diabetes, CVD, and an increased risk for AD 
(Martins et al., 2006). 
In the Honolulu-Asia Aging Study (HAAS), results suggest that midlife 
elevated diastolic blood pressure may impair Aβ clearance, which can eventually lead 
to AD and cerebral amyloid angiopathy (Shah et al., 2012). It was also observed that 
raised systolic blood pressure increased the risk of AD in later life (Kivipelto et al., 
2001; Atkinson et al., 2009).  
Besides the complex relationship between AD and CVD, it has been shown 
that, in healthy older adults who are free of diagnosable cardiovascular diseases or 
dementia, a simple outpatient measure of cardiac workload, the rate pressure product 
(RPP), is associated with relative impairments in performance on a spatial working 
memory tests; this relationship is not observed in younger subjects (Matthewson et al., 
2011).  RPP (systolic blood pressure × heart rate/100) represents the maximum 
pressure in a structurally normal left ventricle when it is ejecting blood based on the 
number of beats per minute, providing an indirect assessment of myocardial oxygen 
consumption (Gobel et al., 1978).  During the performance of challenging cognitive 
and/or physical tasks, such as exercise, psychological stress and every-day physical 
activity, RPP will increase to meet required metabolic demands (Fredericks et al., 
2005; Atkinson et al., 2009).  If RPP is high in the resting state, we may assume that 
myocardial oxygen use is already elevated in the absence of significant metabolic 
demands.  
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Although the relationship between increased cardiac workload and/or increased 
cardiac risk, and cognitive decline in older adults has been reasonably well-established 
(Jefferson et al., 2014; Jefferson et al., 2015), it is unclear just how strong the 
relationship is between cardiac function and biomarkers of prodromal disease in 
individuals without cardiovascular disease at high risk for preclinical AD.  Given this 
gap in the literature, we sought to determine whether there was any association 
between cardiac workload, working memory and cortical Aβ burden in 63 cognitively 
normal older adults.  We predicted that increased RPP at rest would be inversely 
related to performance on the spatial working memory test, but only for individuals 
with neuroimaging evidence of amyloid aggregation consistent with prodromal AD. 
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CHAPTER 3 
 
METHODOLOGY 
 
Subjects: Participants were recruited by serial referrals from two memory disorder 
centers in Rhode Island and from broad print advertising to the community.  All 
subjects were cognitively normal midlife adults (N=63, Mage= 62.8; range = 55 to 75 
years-old), with first-degree family histories of AD and with complaints of significant 
subjective memory impairment (SMI).  All subjects presented with normal 
neurological exams, had MMSE scores > 27, no current Axis I or II psychopathology, 
no reported significant cardiovascular disease and no current alcohol or substance 
abuse.  All subjects also performed well within normal limits on episodic memory 
testing, including a word-list learning test and computer-administered measures of 
working memory, concentration and attention (Lim et al., 2015). None of the subjects 
met NIA-AA diagnostic criteria for mild cognitive impairment (Albert et al., 2011).  
Although all subjects denied cardiologic conditions or diagnoses, we could not 
exclude the possibility of asymptomatic cardiologic conditions or the presence of 
occult cerebrovascular disease in some individuals.   
 Subjects were separated into two groups based on PET amyloid imaging 
results with 15 subjects having Florbetapir uptake SUVr scores ≥ 1.10, and 48 subjects 
having SUVr scores < 1.10.  Additionally, all 15 subjects with evidence of significant 
neocortical amyloid aggregation failed a micro-dose scopolamine “cognitive stress 
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test” (Lim et al., 2015; Snyder et al., 2014) suggesting the presence of prodromal 
cholinergic tone disruption and supporting the prediction of preclinical AD.  
 With respect to genetic risk for AD, eight of the 15 individuals (53%) in the 
amyloid positive group (SUVr scores ≥ 1.10) had at least one copy of the APOE ε4 
allele, whereas 20 of 45 individuals (45%) in the amyloid negative group (SUVr 
scores < 1.10) had at least one copy of the APOE ε4 allele. Roughly half of the 
subjects in each group presented with this additional risk factor for AD, but due to 
small sample sizes we were not able to further evaluate the specific effect of APOE 
genetic risk on the relationship between RPP and cognitive performance.  Subject 
demographics are provided in Table 1. 
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            Table 1. Demographic Characteristics 
 
 
             *Note: SUVr = standardized uptake value ratio; GDS = Geriatric Depression Scale; DASS 
              Depression, Anxiety, and Stress Scale; MMSE = Mini Mental State Examination; ISLT = 
              International Shopping List Test; bolded value is significant at the p<.001 level.
 Main Outcome Full sample 
(n = 63) 
Aβ+ 
(n = 15) 
Aβ-  
(n = 48) 
  
  N (%) N (%) N (%) p Cohen’s 
d 
Sex No. of female 39 (61.9%) 11 (73.3%) 28 (58.3%) .296  - 
       
Age No. of years 62.79 (5.35) 63.93 (6.31) 62.44 (5.04) .349 0.28 
Education No. of years 17.21 (2.77) 17.47 (3.46) 17.14 (2.55) .689 0.12 
Florbetapir 
PET SUVr 
Standardized 
Uptake Value 
ratio 
1.04 (0.19) 1.30 (0.20) 0.95 (0.08) .000 2.95 
GDS Total Score 1.86 (2.16) 1.60 (1.45) 1.94 (2.35) .602 -0.16 
DASS 
Depression 
Subscale 
Total 
Depression 
Subscale Score 
3.56 (6.70) 2.60 (2.59) 3.87 (7.56) .526 -0.19 
DASS 
Anxiety 
Subscale 
Total Anxiety 
Subscale Score 
2.73 (4.53) 2.40 (3.58) 2.83 (4.83) .752 -0.09 
DASS 
Stress 
Subscale 
Total Stress 
Subscale Score 
6.73 (6.77) 6.67 (4.55) 6.74 (7.38) .969 -0.01 
Body Mass 
Index 
Body Mass 
Index 
26.69 (5.50) 28.66 (7.95) 26.07 (4.41) .113 0.48 
MMSE Total Score 29.05 (1.02) 28.93 (1.16) 29.08 (0.99) .624 -0.15 
ISLT Total 
Recall 
Total words 
recalled 
25.59 (4.22) 24.73 (4.46) 25.85 (4.16) .374 -0.26 
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Neuroimaging: A 370MBq (10 mCi +/- 10%) bolus injection of F-florbetapir 
was administered intravenously [21]. Approximately 50 minutes post-injection, a 20-
minute PET scan was performed with head CT scan for attenuation correction 
purposes. Because this is a study of relatively healthy midlife adults for whom only a 
minority of subjects present in the preclinical stage of AD, we had no reason to 
suspect generalized neocortical amyloid deposition and instead focused our attention 
on the anterior cingulate region-of-interest (ROI) (Lim et al., 2015).  The PET 
standardized uptake value (SUV) for the anterior cingulate (ACC) region was summed 
and normalized to the whole cerebellum SUV, resulting in an ACC-to-cerebellum 
ratio termed SUV ratio (SUVr). An ACC SUVr threshold of ≥1.1 was used to 
discriminate between Aβ- and Aβ+; both the rationale for selection of this specific 
ROI, and these methods, are described by Lim et al (2015) (Lim et al., 2015).  For all 
cases, Aβ positivity was confirmed by consensus over-read by two board-certified 
radiologists who were also board-certified in Nuclear Medicine. 
 
Cardiac Measures and Cognitive Assessment: Blood pressure and heart rate data 
were collected while subjects were at rest, with all assessments occurring between 
0800 and 0900.  Subsequent to the collection of these measures, all subjects completed 
the Groton Maze Learning Test (GMLT; www.cogstate.com).  The GMLT is a 
computer-administered hidden maze test that differentially measures both spatial 
working memory and reasoning/problem solving cognitive functions (Thomas et al., 
2014). For the purpose of this study, the total errors score was relied on as the 
principal measure of spatial working memory.  In addition, the number of rule-break 
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errors was obtained as an additional measure of executive functioning (Papp et al., 
2011). Rule-break errors are made when subjects fail to adhere to any of three very 
simple rules (e.g., not to move diagonally) that, when followed, facilitate performance 
on the test.  Finally, we chose to also look at the timed chase test of the GMLT 
(Snyder et al., 2005; Thomas et al., 2008), as a measure of simple visuomotor speed.  
The GMLT, and these three component scores, has been described previously both in 
terms of performance within the context of studies with healthy elderly adults (Snyder 
et al., 2005; Thomas et al., 2008; Pietrzak et al., 2007; Chen et al., 2010), as well as in 
mild cognitive impairment (MCI) (Papp et al., 2011).  All subjects completed an initial 
practice run of the GMLT to allow for initial task familiarity; after a 10 minute break 
all subjects repeated the GMLT as a baseline assessment. 
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CHAPTER 4 
 
FINDINGS 
 
A moderate relationship was found between increasing cardiac workload (at 
rest) and increasing impairments on the GMLT measure of spatial working memory 
(total errors score) for the 15 subjects with evidence of substantial neocortical amyloid 
aggregation (Florbetapir PET imaging); however, after adjustment for multiple 
comparisons, the effect was not statistically significant (p=0.0429, adj p=0.0858). This 
association was nonetheless significantly different than that observed for the other 48 
subjects (interaction p=0.0307), in whom no association was evident (p=0.3974, adj. 
p=0.3974). This relationship remained significant after statistical control for education 
(p=0.0354), sex (p=0.4708), body mass index (p=0.3668) and age (p = 0.9425). 
The effect of Aβ moderation was more apparent with regards to the 
relationship between RPP and increasing impairments on the GMLT measure of 
reasoning/problem-solving (rule-break errors score). Here, RPP increased by 
approximately 11.2 mmHg*bpm (95%, CI 3.5-18.8 mmHg*bpm; p=0.0014, adj. 
p=0.0028) for the 15 Aβ positive subjects (see Figure 1). This relationship was 
significantly stronger than for the 48 subjects (interaction p=0.0017) without any 
evidence of cortical Aβ plaque burden, in whom no association was evident 
(p=0.6230, adj. p=0.6230). This relationship remained significant, after statistical 
control for education (p=0.0256), sex (p=0.9586), body mass index (p=0.3999) and 
age (p = 0.9727).  By comparison, the correlation between systolic blood pressure
 13 
 
alone and the GMLT rule-break errors score for the Aβ positive group was 
comparatively modest but still significant (Adj. R2 = 0.21, p <0.05), and there was no 
such correlation observed for the Aβ negative group (Adj. R2 = -0.02, NS). 
Finally, no significant relationship between RPP and the GMLT measure of 
simple visuomotor speed (timed chase test) were observed, regardless of Aβ status. 
 
FIGURE 1.  Increasing impairment on the Reasoning/Problem-Solving measure of the Groton 
Maze Learning Test (GMLT). In Healthy Midlife Adults who present with evidence of 
elevated neocortical Aβ aggregation (PET Florbetapir anterior cingulate SUVr ratio > 1.10; N 
= 15), the Rate Pressure Product (RPP) increased by approximately 11.2 mmHg*bpm (95%, 
CI 4.5-17.8 mmHg*bpm; adj. p=0.0028) for every doubling in the total number of rule-break 
errors over the 5 learning trials. This association was significantly different (interaction 
p=0.0017) than was seen for individuals without such neuroimaging evidence of preclinical 
AD (N = 48), in whom no association was evident (adj. p=0.6263). 
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With all 63 subjects considered together, there is a small-to-moderate 
relationship between neocortical Aβ burden and RPP (p = 0.0329), with increasing 
cardiac workload at rest associated with greater neocortical amyloidosis. This 
relationship remained significant, after statistical control for education (p = 0.2011), 
gender (p = 0.0476), body mass index (p = 0.1846), and age (p = 0.8548).
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CHAPTER 5 
 
CONCLUSION 
 
This study may be the first to demonstrate that increased cardiac workload, as 
a surrogate of myocardial oxygen use at rest, has a small to moderate correlation with 
neocortical amyloidosis in midlife adults with preclinical AD. Approximately one-
quarter of the sample (N=15) met neuroimaging criteria for pre-clinical stage of the 
disease. This relationship is modest, and RPP does not have the potential to serve as a 
biomarker of cortical Aβ burden in preclinical AD.  Rather, we were impressed that a 
significant relationship even existed given that our study subjects are all relatively 
young, healthy, living independently and free of any diagnosable cardiological or 
neurological diseases.  Limitations of this current study and report include the small 
sample sizes (particularly for the amyloid positive group, N = 15) and the cross-
sectional design of these planned comparisons.  
 We have shown previously that, in older adults, elevated resting state RPP is 
associated with relatively poor cognitive performance on a modified version of the 
GMLT, but this prior cohort was not specifically screened for possible occult disease 
(Mathewson et al., 2011). The results presented here corroborate that initial report as 
we observed a strong linear correlation between RPP and performance on both the 
spatial working memory and reasoning/problem-solving measures of the GMLT, with 
increasing cardiac workload at rest associated with greater impairment on the spatial 
working memory measure of this test, but only for those subjects with PET amyloid 
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imaging evidence of likely preclinical AD.  By comparison, this association was not 
observed for the GMLT measure of simple visuomotor speed, suggesting that this 
relationship might only be observed for cognitive measures that require executive 
functions (including working memory). 
 Taken together, these results support a relationship between at least one major 
neuropathologic pathway for the disease (the aggregation of Aβ protein plaques in the 
neocortex) and less efficient myocardial oxygen use in the absence of significant 
metabolic demands, which appears related to a relative decrement in cognitive 
function.  We are currently re-evaluating the subject cohort described in this report to 
determine whether indices of phasic vagal cardiac control, such as their resting sinus 
arrhythmia (RSA) and heart rate variability (HRV) measures, are also related to 
cortical amyloidosis in preclinical AD since both cardiac phenomena are directly 
modulated by muscarinic and nicotinic cholinergic autonomic neurotransmission.   
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